Key Players Focusing On Companion Diagnostics Market for Breast and Lung Cancer

From: Markets and Markets
Published: Fri Jun 23 2017

The "Companion Diagnostics Market by Technology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer) & End-user (Pharmaceutical Companies, Reference Lab)- Global Trends & Forecasts to 2019". The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3136.9 million in 2014, at a CAGR of 22.7% during the forecast period (2014 to 2019).

Browse 57 market data tables with 36 figures spread through 142 pages and in-depth TOC on "Companion Diagnostics Market"
Early buyers will receive 10% customization on reports.

"Next-generation Sequencing (NGS)-based Companion Diagnostic Tests to Capture a Larger Market Share in Chronic and Life Threatening Diseases in the Future."

Advanced technologies such as next-generation sequencing (NGS), increasing adoption of companion diagnostic kits/tests by the pharmaceutical industry, and encouragement from regulatory bodies are expected to boost the global market.

Increasing costs of drug discovery; continuous focus on customized medicines for cancer; infectious, cardiovascular, neurological, and autoimmune diseases; and the need for technically advanced diagnostics has stimulated pharmaceutical firms to enter into the market.

Get The PDF Brochure For This Report@

In 2013, many new molecular entities (NMEs) were approved by a pharmacogenomics biomarker from the FDA. However, non-validated home brew tests employed by reference laboratories pose a major threat to validated companion diagnostic kits globally, as they are easily available and have faster approval procedures. In addition, different reimbursement policies followed by different regions may hinder the growth of the market.

NGS-based companion diagnostics is one of the major factors that will drive the market owing to its capability of identifying multiple genes at a single time. This in turn encouraged the adoption of diagnostic tests in the earlier clinical phase and ensured accurate treatments.

Ask For a Discount@

Currently, NGS-based companion diagnostic tests are available for cystic fibrosis and the companion diagnostic manufacturers are engaged in developing tests for other chronic and life threatening diseases. To capture this market, pharmaceutical firms are striving to enter into the global market through strategic acquisitions and collaborations with NGS platform diagnostic firms.

Moreover, the end results of NGS is superior as compared to other technologies, as NGS provides a wider definition of genome sequencing that will fuel the adoption of NGS-based companion diagnostic in the future.

This study also illustrates the major market players who have made a remarkable contribution in the global market. The major players of this market are Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), Thermo Fisher Scientific Inc. (U.S.), and QIAGEN N.V. (Netherlands).

About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Rohan
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441
Company: Markets and Markets
Contact Name: Mr. Rohan
Contact Email:
Contact Phone: 8886006441

Visit website »